Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106585 · ClinicalTrials.gov registry record · Phase 1
Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
A Phase 1 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT02106585 is a Phase 1 study that has completed, run by Akros Pharma. The registered enrollment target is 94 participants.
The verdict
NCT02106585, a Phase 1 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics) of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to evaluate the effect of food on the PK of JTT-251 in healthy subjects.
Interventions
- DRUG JTT-251 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106585
The ClinicalTrials.gov registry entry for NCT02106585 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JTT-251 or Placebo is the first listed.
NCT02106585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02106585 about?
NCT02106585 is a clinical study titled "Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects". The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics) of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to evaluate the effect of food on the PK of JTT-251 in healthy subjects.
What is the current status of trial NCT02106585?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2014-03. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02106585?
The interventions under investigation include: JTT-251 or Placebo (DRUG).
Who is sponsoring clinical trial NCT02106585?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.